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Introduction
Thrombosis is a disease that affects the young and the old.
Differences between the ages concern the frequency of throm-
bosis and its risk factors. Here, we will present epidemio-
logic data on venous and arterial thrombosis with regard to
the incidence for different age categories, with a view on
morbidity and mortality. For the risk factors, the focus will
be on venous thrombosis, with a review of the risk profiles
specific to children in the first year of life, older children and
young adults, which are three distinct groups with regard to
venous thrombosis. Since in young adults the risk factors that
play a role are qualitatively the same äs those that play a role
in older adults and the elderly, risk factors that are specific to
young adults will be dealt with in detail: oral contraceptives,
pregnancy and puerperium. Finally, we will present new data
on the quantitative iraportance of several risk factors for
venous thrombosis, concerning the frequency and the number
of risk factors required for thrombosis in different age groups.
Incidence of venous and arterial thrombosis
Morbidity data
Thrombosis manifests itself mainly äs myocardial infarction,
cerebral infarction, and venous thromboembolism. Each of
these occurs with an incidence of 1-3 per 1000 individuals
per year (1,2,3). The incidence rates of thrombosis are only
known by approximation, since they require very large
studies or regional registries, that each have their specific
shortcomings - for instance, even the largest studies will have
considerable statistical uncertainty, hospital registries do not
include individuals who died before admission, and statistics
based on death certificates suffer from misclassified diag-
noses. The incidence is distributed extremely unevenly over
the ages, which on the one hand makes thrombosis uncom-
mon in young individuals, while on the other hand thrombo-
sis is the leading cause of death in the elderly. Table l shows
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Table 1. Incidence of acute myocardial infarction (AMI), cerebral
infarction (CI) and venous thromboembolism (VTE): morbidity data
Incidence per 100,000 per year
age AMI1 CP VTE3
0-14
15-24
25-39
40-54
0.1
0.7
18.6
175.6
1.0
1.9
6.6
45.4
0.6
20.2
39.3
74.2
Information on hospital discharge diagnoses in 1994 kindly sup-
plied by SIG Zorginformatie, Landelijke Medische Registratie
(LMR), Utrecht (3). The 1994 discharge data cover 99.3 percent of
the Netherlands. Incidence rates calculated with population age-dis-
tribution data for 1994 from the Central Bureau of Statistics, The
Hague (4).
'ICD code 410: acute myocardial infarction, 2ICD codes 434,436:
cerebral infarction, 3ICD codes 415, 451,453, 671.3, 671.4, 671.5:
deep venous thrombosis, pulmonary embolism.
the incidence of the major types of arterial and
venous thrombosis in the Netherlands, äs calculated from
hospital registries. Until age 40, venous thrombosis is the most
common form of thrombosis, after which the incidence of
myocardial infarction increases very rapidly and becomes the
most common form of thrombosis.The incidence rates are
also not evenly distributed over the sexes: myocardial infarc-
tion is more frequent among men than among women; up to
age 55, myocardial infarction occurs four to five times more
often in men than in women. Cerebral infarction is slightly
(about two-fold) more common in women until age 40, after
which this distribution reverses. Venous thrombosis is more
often seen in women than in men, which difference is most
pronounced in the reproductive age (two- to three-fold
difference). Between age 15 and 39, a woman has a 5-fold
higher risk of experiencing a venous thrombotic event than
an arterial thrombosis (3).
Mortality data
Table 2 shows Dutch mortality rates for acute myocardial
infarction, cerebral infarction and venous thromboembolism
(4). Until age 40, death from any form of thrombosis is very
rare, and occurs in less than one per 100,000 individuals per
year. After age 40, myocardial infarction and, to a lesser
l
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Table 2. Incidence of death from acute myocardial infarction (AMI),
cerebral infarction (CI) and venous thromboembolism (VTE): mor-
tality data
Mortality per 100,000 per year
age AMI' CI2 VTE3
0-14
15-24
25-39
40-54
0.03
0.3
3.0
31.5
0
0.1
0.4
3.6
0
0.3
0.4
1.1
National mortality statistics for 1994 from the Central Bureau of
Statistics, The Hague (4).
'ICD code 410: acute myocardial infarction, 2ICD codes 434, 436:
cerebral infarction, 3ICD codes 415, 451, 453, 673: deep venous
thrombosis and pulmonary embolism
extent, cerebral infarction, begin to take their toll. When
compared to the morbidity figures (which comparison should
be made with some caution because of the shortcomings of
these different estimates äs mentioned above), it is clear that
venous thrombosis has a much lower lethality than myocar-
dial infarction: even though venous thrombosis is more
common in the young than arterial thrombosis, less individu-
als die from venous than from arterial thrombosis. In
children, thrombosis is so rare that mortality rates cannot be
compared between the subtypes (venous and arterial) of
thrombosis. Between age 15 and 24, mortality from venous
thrombosis is slightly more frequent man from arterial throm-
bosis - the difference again being most pronounced in women.
Risk factors for venous and arterial thrombosis
Table 3 lists several of the risk factors for myocardial infarc-
tion, cerebral infarction and venous thromboembolism
(5-7). The risk factors for myocardial infarction and cerebral
infarction show most overlap, although some risk factors are
more pronounced for myocardial infarction (eg, male sex,
hypercholesterolemia) than for cerebral infarction. Some
factors are associated with an increased risk of all types of
thrombosis, eg, oral contraceptives, hyperhomocysteinemia,
lupus anticoagulant and high levels of fibrinogen (8,9).
The risk factors for venous thrombosis are different
Table 3. Risk factors for myocardial infarction, cerebral infarction and
venous thromboembolism
Myocardial
infarction
Cerebral
infarction
Venous
thromboemboüsm
hypertension
smoking
diabetes mellitus
hypercholesterolemia
obesity
oral contraceptives
hyperhomocysteinemia
lupus anticoagulant
high fibrinogen
hypertension
smoking
diabetes mellitus
hypercholesterolemia
obesity
oral contraceptives
hyperhomocysteinemia
lupus anticoagulant
high fibrinogen
surgery/trauma/
immobilisation
malignancy
pregnancy/puerpenum
factor V Leiden
deficiency of PC/PS/AT
oral contraceptives
hyperhomocysleinemia
lupus anticoagulant
high fibnnogen
high factor Vlll levels
because they are not related to atherosclerosis. Classical risk
factors for venous thrombosis are those associated with
tissue damage and stasis, ie, trauma, surgery and immobili-
sation. Abnormalities associated with the hemostatic System
are prominent in venous thrombosis, and together deficien-
cies of protein C (PC), protein S (PS), antithrombin (AT) and
carriership of factor V Leiden or resistance to activated
protein C (APC), account for 25-35 percent of all occurrences
of venous thrombosis. This implies that heritability plays a
more important, or at least a more obvious, role in venous
than in arterial thrombosis.
Venous thrombosis in children
Venous thrombosis in children is far less common than in
adults and has a distinct presentation and etiology. In a regis-
try of Canadian children with thrombosis, the incidence of
venous thrombosis between ages l month and 18 years was
estimated at 0.7 per 100,000 per year (10). This figure is in
close accordance with the estimate of 0.6 per 100,000 per
year for the ages 0-14 based on the Dutch hospital discharge
registry shown in table 1.
In the first year of life, venous thrombosis occurs either
in association with indwelling venous catheters, or äs renal
vein thrombosis. The association with venous access devices
implies that the location of the thrombosis often involves the
upper extremities. In the 60 children with venous thrombosis
in the first year of life from the Canadian registry, 21
suffered renal vein thrombosis, while all but one of the 39
otherpatients had a venous catheter (11). These latter throm-
boses occurred in a variety of locations of which the superior
vena cava and vena femoralis were the most common.
Renal vein thrombosis becomes manifest in the first few
days af ter birth. Although its etiology is obscure, it is assumed
that renal vein thrombosis has its onset before birth. In
contrast to other forms of childhood thrombosis, renal vein
thrombosis has a clear sex difference, affecting male newboms
twice äs often äs newborn girls (11). An exceedingly rare and
severe form of thrombosis in the newborn is caused by ho-
mozygous deficiencies of protein C or protein S (12-13).
These children develop extensive thrombosis with purpura
fulminans shortly after birth. Homozygous antithrombin de-
ficiency may not be compatible with life (14).
In older children, venous catheters remain one of the most
frequent triggering factors for thrombosis, and are reported
in at least 25 percent of the patients (10,15,16). Other
frequently encountered risk factors are surgery and trauma,
malignancy, auto-immune disorders (sytemic lupus
erythematodes, lupus anticoagulant) and infections. Rarely,
an inborn error of metabolism leads to a thrombotic tendency,
eg homocystinuria, which has a prevalence of 1:335,000 live
births (8,17). After the first year of life, thrombosis occurs
about äs frequently in male and female children (15). The
incidence has a peak in the first year, becomes very low
during the next 10 years and subsequently slowly increases
with age (10). In children with venous thrombosis, it is only
very rarely that no triggering event can be found; in almost
half of the children three or four risk factors are present
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simultaneously (10). In a substantial number of children
disorders of hemostasis can be found: inherited deficiencies
of antithrombin, protein C, protein S were reported in 25-30
percent of children with venous thrombosis (10,16). This
clearly exceeds the prevalence of these disorders in consecu-
üve adult patients with venous thrombosis (18,19). Even in
these children with deficiencies, the thrombosis did not
occur spontaneously, and the hemostatic defect only became
apparent because thrombosis occurred when one or more
acquired risk factors were also present (10,15). This has
etiological and practical consequences: it shows that venous
thrombosis is a multicausal disease, which becomes most
evident in children, who have not yet accumulated age-asso-
ciated risk factors; and it implies that in children contrary to
the Situation in adults it is worthwhile to investigate defects
in hemostasis even if other risk factors seem to 'explain' the
thrombotic event.
Venous thrombosis in young adults
Among adults, the major risk factors for venous thrombosis
can be divided in acquired and genetic risk factors. The
importance of each depends on its prevalence in the general
population and its relative risk. The prevalence of the acquired
risk factors is strongly dependent on age, with pregnancy,
puerperium and oral contraceptives being limited to the young,
and malignancies, surgery and immobilisation being more
prevalent among the elderly than among the young. The
prevalence of some risk factors, such äs use of oral contra-
ceptives and hormonal replacement therapy will also vary
between societies. For some risk factors, notably
hyperhomocysteinemia and high levels of factor VIII, it is
not clear to what extent they are affected by genetic or
acquired determinants.
Although deficiencies of protein C, protein S and anti-
thrombin have a high relative risk, they are not the most im-
portant risk factors for venous thrombosis because they are
very rare. Common abnormalities are APC-resistance, which
increases the risk of thrombosis seven-fold and is found in
3-7% of Caucasians (20-24), high levels of factor VIII, which
are found (FVffl:C>150IU/dl) in 11 percent of the popula-
tion and increase the risk of venous thrombosis six-fold (25),
and hyperhomocysteinemia, which is found (homocysteine
> 18.5:mol/l) in 5-10 percent of the population and increases
the risk of thrombosis two-fold (26,27). The factor II variant
(20210 G>A) has been found in 2.3 percent of healthy
controls, and increases the risk tnree-fold (28). These figures
allow the computation of population-attributable risks, which
indicate how much of the total incidence in the population
can be attributed to a specific exposure or risk factor (29).
For factor VIILC levels >150IU/dl this is 35 percent, ie, 35
percent of all events of deep-vein thrombosis can be attrib-
uted to high factor VIII levels; for protein C deficiency this is
only three percent.
Oral contraceptives and venous thrombosis
Numerous reports in the 1960s and 1970s have followed
Jordan's case report of pulmonary embolism associated with
the use of a oral contraceptive in 1961 (30,31,32). Although
over the decades the oestrogen content of the oral contracep-
tive pill has gone down in an attempt to lower the risk of
thrombosis, this risk has not disappeared. In a recent study
from the WHO, oral contraceptive use was associated with a
4.2-fold increased risk of thrombosis (33); in a Dutch study
the age-adjusted relative risk of users versus non-users was
six (34). Because oral contraceptives are used by young
women who have a very low risk of venous thrombosis, the
absolute risk remains low. On the other band, since many
young women use oral contraceptives, the majority of the
thrombotic events in the younger age groups in women can
be attributed to the use of oral contraceptives.
Recently, it has been shown in several studies that the
progestagen component in oral contraceptives also has a
thrombogenic potential: products containing desogestrel or
gestodene, so-called third generation progestagens, confer a
two-fold higher risk of thrombosis than oral contraceptives
with a second generation progestagen (often levonorgestrel)
(35-38). This higher nsk associated with third generation
progestagens remained after adjustment for age, family
history, duration of use, parousness, obesity, factor V Leiden
carriership (35-38). Among the youngest women, the
relative risk was highest: among 15-19 year old women, a
third-generation progestagen containing oral contraceptive led
to a 7-fold higher risk than a second-generation progestagen
containing oral contraceptive; in the age group 20-24 there
was a four-fold risk increase (37).
The factor V Leiden genotype acts synergistically with
the use of oral contraceptives on the risk of deep-vein throm-
bosis: the incidence of deep-vein thrombosis for the age-group
15-49 years was estimated at 0.8 per 10,000 women per year
for non-users with the normal genotype, 3.0 per 10,000
women-years for users of oral contraceptives with the nor-
mal genotype, and 5.7 per 10,000 women-years for non-us-
ers with thelactor V Leiden genotype, and the risk became
28.5 per 10,000 women-years for oral contraceptive users with
the factor V Leiden genotype (34). This synergistic effect was
most pronounced when women used a third-generation
contraceptive (37). There is an excess of oral contraceptives
using women among thrombosis patients with homozygous
factor V Leiden (23); in one series, 80 percent of the
homozygous women with thrombosis were users of or#l
contraceptives at the time of the thrombosis (39). A very high
risk of thrombosis has also been shown for women with the
more rare forms of familial thrombophilia who use oral
contraceptives, especially in antithrombin deficiency (40).
Pregnancy and venous thrombosis
It is unclear how large a risk of thrombosis is conferred by
pregnancy and the puerperium. In two large series, venous
thrombosis was reported in 0.13 per 1000 pregnancies (41)
and 0.7 per 1000 pregnancies (42). Taking the average dura-
tion of pregnancy into account, these are incidence rates of
0.17 and 0.93 per 1000 pregnant-women-years. This is slightly
higher than the risk of non-pregnant women in these
age-groups. In a direct comparison in the Leiden Throm-
bophilia Study pregnancy was associated with a four-fold
increased risk of venous thrombosis (43).
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The risk of thrombosis is much greater in the puerperium
than in pregnancy. It has been estimated that 2.3 to 6.1 of
1000 deliveries are followed by thrombosis (41,42). A woman
therefore has a 3- to 5-fold higher risk of developing throm-
bosis shortly after than during pregnancy; since the postpar-
tum is much shorter than the period of pregnancy, this
implies that the incidence of thrombosis (ie, per unit of time)
is at least 20-30 fold higher postpartum than during preg-
nancy.
All thrombophüias lead to an increased risk of thrombo-
sis during pregnancy (44-46). Most of these are rare and there-
fore concerns only a fraction of all pregnancies. This is
different for factor V Leiden, which has been found among
20-60 percent of women with thrombosis in pregnancy
(47-49).
;· Frequency of risk factors for venous thrombosis
Whereas some types of thrombosis appear to be specific for
young individuals, ie, renal vein thrombosis in the newborn,
and some risk factors are only found in the young, ie, oral
contraceptives and pregnancy, many risk factors increase the
risk in the young and the old. The distribution of the risk
factors over the age groups, however, may differ. Table 4
shows the prevalence of several major risk factors for throm-
bosis, äs found in the Leiden Thrombophilia'Study (LETS),
for contrasting age categories:
Surgery, hospital admissions, factor V Leiden and high
levels of factor VIII appear äs important risk factors in young
and older individuals alike. The prevalence of some factors
is different for different age groups: the increased levels of
factor VIII in those aged 55 and older is an age-effect, äs is
an increasing frequency of surgery, hospital admissions and
other medical conditions that can be seen with finerage-strati-
fication. The absence of a risk associated with high levels of
homocysteine among young individuals is noteworthy; how-
ever, it is in contrast to other reports that showed a high preva-
lence of hyperhomocysteinemia in young individuals with
thrombosis (50). The hereditary risk factors are more preva-
lent among patients who experience their first thrombotic
event at a younger age than those who do so at an older age,
Table 4. Risk factors for deep-vein thrombosis by age
Risk factor < 40 years eed 55 +
surgery/hospital
admission
factor V Leiden
factor II 202 10G6A
PC/PS/AT deficiency
high factor VIII
hyperhomocysteinemia
cases
(n=I60)
%
30.0
23.1
6.9
8.8
25.0
11.2
controls
(n=161)
%
5.6
3.7
3.7
2.5
11.8
10.6
cases
(n=127)
%
24.4
18.1
4.7
3.9
48.0
24.4
controls
(n=124)
%
4-8
3.2
2.4
0.8
29.8
12.2
Frequency of risk factors are shown for cases and controls younger than 40
(ränge 15-39) and older than 54 (ränge 55-72). Surgery and hospital admis-
sions refer to all such events in the year prior to the thrombosis or a similar
date in controls; deficiencies of protein C (PC), protein S (PS) and anti-
thrombin (AT) were defmed äs results below the lower limit of normal on
two separate occasions; high factor VIII are FVIII:C levels exceedmg 150
[U/dl; hyperhomocysteinemia is a non-loadmg plasma homocysteine level
exceeding 18.5:mol/l.
but this effect is not very pronounced. This seems in contrast
to the marked relation with thrombosis at a young age
reported in families with familial thrombophilia; however,
that is the result of those families having been selected mainly
on the occurrence of thrombosis at a young age (51). These
genetic abnormalities are less prevalent in the older than in
the younger healthy controls, which points to the high throm-
botic risk of these defects: few individuals carrying these
defects grow old without experiencing thrombosis.
N umher of risk factors requiredfor thrombosis
In children, three or four risk factors are often required to
precipitate thrombosis. Recently, it has become clear that in
adults, too, thrombosis is a multicausal disease. Protein C
deficiency appeared more severe in families with familial
thrombophilia than in relatives of asymptomatic blood
donors (52-54), because in these families several abnormali-
ties were present (55). It seems plausible that in order for
thrombosis to occur, several risk factors, genetic and acquired,
need to be present simultaneously, and that this is even more
so for thrombosis to occur at a young age; hence the finding
of several risk factors in young children, and in families with
thrombophilia, which are often selected based on the occur-
rence of unexplained thrombosis at a young age.
Table 5 shows the number of risk factors, from a total of
seven major risk factors, found in patients and controls in
various age groups (data from LETS). Among individuals
aged 40 and less, äs well äs among those aged 55 and more, a
large proportion of the cases has one or more of these seven
major risk factors. The relative risk of thrombosis rises sharply
with the number of risk factors; among those aged less than
forty, relative to those with none of these risk factors, those
with one risk factor have a 2.4-fold increased risk, those with
two risk factors a 7.7-fold increased risk, whereas for those
with three or more risk factors the relative risk exceeds 20.
Among the individuals aged 55 and older, a similar relation
between the number of risk factors and the relative risk can
be observed. A difference between the older and younger age
groups is a higher proportion of individuals in the young age
category, among cases and controls alike, with two or more
risk factors. This indicates that in the young age group a
combination of several risk factors will lead to thrombosis,
leaving very few to grow old without thrombosis while
carrying such a combination of risk factors.
Table 5. Number of thrombosis risk factors in different age categories
Risk factors < 40 years aged 55 +
none
1
2
3
4
5-7
cases
(n=160
16.9
31.9
35.6
11.9
3.8
0
controls
(n=161)
47.8
37.3
13.0
1.2
0.6
0
cases
(n=127)
22.8
37.8
33.9
3.9
1.6
0
controls
(n=124)
54.8
38.7
4.8
1.6
0
0
The risk factors that are counted are those of table 4: surgery/hospital admis-
sion, factor V Leiden, factor II 20210 G6A, clotting inhibitor (PC/PS/AT)
deficiency, high factor VIII, hyperhomocysteinemia, and oral contraceptive
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Conclusion
The incidence of thrombosis strongly depends on age: it is a
very rare disorder in the young, and a common affliction in
the elderly. Thrombosis occurs when a sufficient number of
risk factors are present simultaneously. In children, three or
four risk factors are required before thrombosis occurs,
whereas in individuals aged 55 and older thrombosis will
almost invariably occur when two or more risk factors are
present The number of risk factors required to cause throm-
bosis decreases with age, which itself therefore appears äs a
strong risk factor for thrombosis. It seems likely that ageing
introduces additional risk factors, with vessel wall changes,
with a different composition of the Wood, or with altered
mobility, which may all add to the risk profile, necessitating
fewer additional risk factors for thrombosis to occur. Or,
viewed from a different angle: the decreasing number of risk
factors required to cause thrombosis with increasing age,
explains why the incidence of thrombosis rises with age.
Summary
Thrombosis occurs most often äs myocardial infarction,
cerebral infarction or venous thromboembolism, ie, deep-vein
thrombosis and pulmonary embolism. The incidence of all
types of thrombosis is strongly dependent on age. Among
young individuals, up to age 40, venous thrombosis is the
most common form of thrombosis. The risk factors for arte-
rial and venous thrombosis differ, and among the latter disor-
ders of hemostasis appear to be more prominent.
In children venous thrombosis appears almost exclusively
in association with venous catheters, with an exception of
the renal vein thrombosis of the newborn, which has an
unknown etiology. In young adults, the risk factors for
venous thrombosis are essentially the same äs in older
individuals, excepting oral contraceptives, pregnancy and
puerperium which are linjited to young women. In young
women, most venous thrombotic events can be attributed to
oral contraceptives.
Venous thrombosis is a multicausal disease: more than
one risk factor needs to be present before thrombosis occurs.
The younger an individual, the more risk factors are required
to precipitate thrombosis: in children often three or four, and
in young adults often two or more.
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